# US 2021/0340610 A1 · A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340610 A1
- Document ID: US20210340610A1
- Status: Published application
- Kind: A1
- Application number: 17/376,919
- Filed: 2021-07-15
- Published: 2021-11-04
- Earliest claimed: 2016-08-17
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Minnie M. Sarwal; Tara K. Sigdel; Joshua Y. Yang
- Web page: https://patentgrep.com/patent/US20210340610A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6853: using modified primers or templates
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6827: {Total protein determination, e.g. albumin in urine}
- G01N 33/6839: {involving dyes, e.g. Coomassie blue, bromcresol green}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 33/70: involving creatine or creatinine
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

## Claims

### Claim 1

A method of detecting an Alu sequence(s) in cell-free (cfDNA) in a biofluidic sample, the method comprising:
obtaining the biofluidic sample from a human;
extracting cfDNA from the biofluidic sample;
forming a reaction mixture by contacting the cfDNA with a nucleic acid probe comprising a nucleotide sequence complementary to at least 20 contiguous nucleotides of the Alu sequence(s) under conditions to allow the probe to hybridize to the cfDNA, wherein the 3′ or 5′ end of the probe is covalently linked to a detectable label, and wherein the cfDNA is not amplified prior to contact with the nucleic acid probe; and
quantifying the amount of cfDNA hybridized to the probe,
thereby detecting Alu copy number in cfDNA in the biofluidic sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detectable label is biotin and the method comprises contacting the detectable label with a streptavidin-linked signal producing agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the streptavidin-linked signal-producing agent produces chemiluminescence, color, or fluorescence.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human received a kidney transplant and the biofluidic sample is taken 0-400 days, or 10-100 days, or 20-50 days, from the date the human received the kidney transplant or over the lifetime of the human from the date of the human receiving the kidney transplant.

### Claim 5 (depends on 1)

A nucleic acid probe for detecting an Alu sequence(s) in cell-free (cfDNA) according to claim 1, comprising a nucleotide sequence of at least 20-300 contiguous nucleotides complementary to SEQ ID NO:1.

### Claim 6 (depends on 5)

The nucleic acid probe of claim 5, wherein the 3′ and the 5′ ends are covalently linked to at least three detectable moieties.

### Claim 7 (depends on 5)

The nucleic acid probe of claim 5, wherein the 3′ or the 5′ ends are covalently linked to a detectable moiety.

### Claim 8 (depends on 7)

The nucleic acid probe of claim 7, wherein the detectable moiety is biotin.

### Claim 9 (depends on 7)

The nucleic acid probe of claim 7, wherein the detectable moiety is a fluorescent molecule.

### Claim 10 (depends on 5)

The nucleic acid probe of claim 5, wherein the nucleic acid probe is complementary to exactly 81 nucleotides of SEQ ID NO:1.

### Claim 11 (depends on 10)

The nucleic acid probe of claim 10, wherein the nucleic acid probe is complementary to at least 20-292 contiguous nucleotides of SEQ ID NO:1.

### Claim 12 (depends on 10)

The nucleic acid probe of claim 10, wherein the nucleic acid probe is complementary to at least 20-180 contiguous nucleotides of SEQ ID NO:1.

### Claim 13 (depends on 10)

The nucleic acid probe of claim 10, wherein the nucleic acid probe is complementary to at least 50-150 contiguous nucleotides of SEQ ID NO:1.

### Claim 14 (depends on 10)

The nucleic acid probe of claim 10, wherein the nucleic acid probe is complementary to at least 70-100 contiguous nucleotides of SEQ ID NO:1.

### Claim 15 (depends on 10)

The nucleic acid probe of claim 10, wherein the nucleic acid probe is complementary to at least 80-90 contiguous nucleotides of SEQ ID NO:1.

### Claim 16

A nucleic acid probe for detecting Alu copy number in a nucleic acid from a biofluidic sample, comprising the nucleic acid sequence of SEQ ID NO:2 covalently linked to a detectable label.

### Claim 17 (depends on 16)

The nucleic acid probe of claim 16, wherein the 3′ and the 5′ ends are covalently linked to at least three detectable moieties.

### Claim 18 (depends on 16)

The nucleic acid probe of claim 16, wherein the 3′ or the 5′ ends are covalently linked to a detectable moiety.

### Claim 19 (depends on 18)

The nucleic acid probe of claim 18, wherein the detectable moiety is biotin.

### Claim 20 (depends on 16)

The nucleic acid probe of claim 16, wherein the detectable moiety is a fluorescent molecule.
